ArticleNeurology and therapy2017

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan.

Takahiko Saida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.